CA2894272A1 - High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms - Google Patents

High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms Download PDF

Info

Publication number
CA2894272A1
CA2894272A1 CA2894272A CA2894272A CA2894272A1 CA 2894272 A1 CA2894272 A1 CA 2894272A1 CA 2894272 A CA2894272 A CA 2894272A CA 2894272 A CA2894272 A CA 2894272A CA 2894272 A1 CA2894272 A1 CA 2894272A1
Authority
CA
Canada
Prior art keywords
granules
sodium
chrome
tablets
punch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2894272A
Other languages
English (en)
French (fr)
Inventor
Latria N. Boudoin
Gregory H. Lambeth
Eric W. Liimatta
Patrick C. Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SI Group Inc
Original Assignee
SI Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49841833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2894272(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/714,768 external-priority patent/US9629809B2/en
Application filed by SI Group Inc filed Critical SI Group Inc
Publication of CA2894272A1 publication Critical patent/CA2894272A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA2894272A 2012-12-14 2013-12-04 High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms Abandoned CA2894272A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/714,768 2012-12-14
US13/714,768 US9629809B2 (en) 2008-07-21 2012-12-14 High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
PCT/US2013/072981 WO2014093073A1 (en) 2012-12-14 2013-12-04 High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms

Publications (1)

Publication Number Publication Date
CA2894272A1 true CA2894272A1 (en) 2014-06-19

Family

ID=49841833

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2894272A Abandoned CA2894272A1 (en) 2012-12-14 2013-12-04 High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms

Country Status (9)

Country Link
EP (1) EP2931261A1 (zh)
JP (1) JP6285952B2 (zh)
CN (1) CN104884048B (zh)
BR (1) BR112015013945A8 (zh)
CA (1) CA2894272A1 (zh)
CL (1) CL2015001621A1 (zh)
HK (1) HK1210591A1 (zh)
MX (1) MX2015007571A (zh)
WO (1) WO2014093073A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7175966B2 (ja) * 2017-08-31 2022-11-21 ノバルティス アーゲー 顆粒剤を調製する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1293764B1 (it) * 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
JP4753567B2 (ja) * 2004-11-19 2011-08-24 旭化成ケミカルズ株式会社 付着性の高い薬物を含有する錠剤の製造方法
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
US9629806B2 (en) * 2008-07-21 2017-04-25 Si Group, Inc. High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
US20120076865A1 (en) * 2010-03-24 2012-03-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances

Also Published As

Publication number Publication date
BR112015013945A8 (pt) 2019-10-08
HK1210591A1 (zh) 2016-04-29
MX2015007571A (es) 2016-04-15
CN104884048B (zh) 2018-11-23
JP6285952B2 (ja) 2018-02-28
WO2014093073A1 (en) 2014-06-19
BR112015013945A2 (pt) 2017-07-11
JP2016508124A (ja) 2016-03-17
EP2931261A1 (en) 2015-10-21
CN104884048A (zh) 2015-09-02
CL2015001621A1 (es) 2015-08-07

Similar Documents

Publication Publication Date Title
JP3589977B2 (ja) 活性成分としてクロドロン酸塩および賦形剤としてケイ化微晶質セルロースを含む医薬製剤
KR101482922B1 (ko) 용융 압출에 의해 제조된, ｎｓａｉｄ와 당 알콜을 포함하는 과립
US5532274A (en) Orally administerable drugs for the treatment of central dopamine deficiency conditions
TWI228414B (en) Pharmaceutical composition comprising carvedilol and hydrochlorothiazide, solid dosage form comprising it, and process for the production of the same
HU229941B1 (en) Preparation of bilayer pharmaceutical tablet comprising telmisartan and a hydrochlorothiazide
US10391072B2 (en) High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
CA2045680C (en) High ibuprofen content granulations
JP2008534522A (ja) 医薬組成物のための複合ステップ製造方法
CA2614468A1 (en) Novel granulation process and granulate produced therefrom
KR20010034703A (ko) 플루옥세틴과 이의 거울상이성질체의 안정한 약형
WO2017221209A1 (en) Pharmaceutical formulations of apixaban
JP4430673B2 (ja) 固形剤形としてのデスモプレッシン薬剤組成物及びその製造方法
JP2004521890A (ja) 非吸湿性バルプロ酸ナトリウム組成物の製造方法
WO1999055373A1 (fr) Compositions contenant du saccharide
US9629809B2 (en) High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
WO2017060920A1 (en) Pharmaceutical compositions
CA2894272A1 (en) High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
KR20110063684A (ko) 알리스키렌을 포함하는 생약 제형 및 용융 압출 과립화에 의한 그의 제조 방법
WO2000071117A1 (fr) Compositions medicinales a liberation immediate pour administration orale
EA015349B1 (ru) Твёрдая разовая пероральная фармацевтическая дозированная форма саквинавирмезилата и способ её изготовления
CA3048968A1 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
EP4321154A1 (en) A tablet of tolvaptan and at least one binder processed with spray granulation
RU2007147951A (ru) Фармацевтические рецептуры немикронизированного (4-хлорфенил){4-(4-пиридилметил)-фталазин-1-ила} и его солей с немедленным высвобождением и высоким содержанием лекарственного средства
WO2005092319A1 (en) Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant
WO2024030098A1 (en) A tablet of tolvaptan and at least one binder processed with spray granulation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181121

FZDE Discontinued

Effective date: 20210831